Several advances of translational research in cardiovascular diseases - 开云网页登录

主管：中华人民共和国教育部
主办：开云网页登录医学院附属瑞金医院
ISSN 1673-6087 CN 31-1978/R

Journal of Internal Medicine Concepts & Practice››2022,Vol. 17››Issue (05): 369-372.doi:10.16138/j.1673-6087.2022.05.004

• Expert forum •Previous Articles Next Articles

Several advances of translational research in cardiovascular diseases

LU Lin, DAI Yang, WANG Xiaoqun, et al

Received:2022-09-05Online:2022-09-30Published:2022-11-04

Abstract

CLC Number:

R587.1
R605

LU Lin, DAI Yang, WANG Xiaoqun, et al. Several advances of translational research in cardiovascular diseases[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 369-372.

References16

[1]	Lam MP, Ping P, Murphy E. Proteomics research in cardiovascular medicine and biomarker discovery[J]. J Am Coll Cardiol, 2016, 68(25): 2819-2830. doi:S0735-1097(16)36779-1pmid:28007144
[2]	Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev, 2022, 27(2): 625-643. doi:10.1007/s10741-021-10105-w URL
[3]	Kullo IJ, Cooper LT. Early identification of cardiovascular risk using genomics and proteomics[J]. Nat Rev Cardiol, 2010, 7(6): 309-317. doi:10.1038/nrcardio.2010.53pmid:20440292
[4]	de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure[J]. Eur Heart J, 2019, 21(3): 272-285.
[5]	Atienza F, Martins RP, Jalife J. Translational research in atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2012, 5(6): 1207-1215. doi:10.1161/CIRCEP.111.970335pmid:23022707
[6]	Nattel S, Heijman J, Zhou L, et al. Molecular basis of atrial fibrillation pathophysiology and therapy[J]. Circ Res, 2020, 127(1): 51-72. doi:10.1161/CIRCRESAHA.120.316363 URL
[7]	Alonso R, Mata P, Muñiz O, et al. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia[J]. Atherosclerosis, 2016, 254: 249-253. doi:S0021-9150(16)31306-5pmid:27594539
[8]	Laugsand LE, Åsvold BO, Vatten LJ, et al. Circulating PCSK9 and risk of myocardial infarction[J]. JACC Basic Transl Sci, 2016, 1(7): 568-575. doi:10.1016/j.jacbts.2016.06.007pmid:30167541
[9]	Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials[J]. Circ Res, 2018, 122(10): 1420-1438. doi:10.1161/CIRCRESAHA.118.311227pmid:29748367
[10]	Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains[J]. Curr Atheroscler Rep, 2015, 17(4): 499.
[11]	Fitzgerald K, Simon A, White S, et al. A subcutaneously administered investigational RNAi therapeutic (ALN-PCSsc), targeting PCSK9 for the treatment of hypercholesterolemia: initial phase Ⅰ study results[C/OL]. http://www.pcsk9forum.org/wp-content/uploads/aln_pcssc_phase_ I_ data.pdf.
[12]	Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden[J]. Eur Heart J, 2017, 38(32): 2499-2507. doi:10.1093/eurheartj/ehx260pmid:28637178
[13]	Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722. doi:10.1056/NEJMoa1615664 URL
[14]	Poller W, Dimmeler S, Heymans S, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives[J]. Eur Heart J, 2018, 39(29): 2704-2716. doi:10.1093/eurheartj/ehx165pmid:28430919
[15]	Ravi S, Mitchell T, Kramer P, et al. Mitochondria in monocytes and macrophages-implications for translational and basic research[J]. Int J Biochem Cell Biol, 2014, 53: 202-207. doi:10.1016/j.biocel.2014.05.019pmid:24863362
[16]	Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection[J]. Sci Signal, 2009, 2(100): ra81.

Related Articles9

Recommended Articles

Metrics

Comments